Gregory Peter Kalemkerian, MD
Dr. Gregory Peter Kalemkerian is a medical oncologist, internist, clinical professor, and researcher at the University of Michigan Rogel Cancer Center whose specialties are lung cancer, malignant pleural mesothelioma, and other thoracic malignancies. As a member of the Thoracic Oncology Team and the Lung Cancer Team, he is an active participant in reviewing patient cases and recommending a treatment plan that is best suited to each patient.[1]
Dr. Kalemkerian has several reasons for having chosen oncology as a career. As he was choosing a specialty, new understandings of the cause of cancer were coming to the forefront that opened up new avenues for research and finding more effective treatment, and that was very exciting. After going into the clinics and treating patients, his passion for oncology grew deeper as he realized how satisfying it was to help patients dealing with lung cancer, mesothelioma, and other thoracic cancers.
Education and Career
Dr. Kalemkerian earned his medical degree at the Northwest University Feinberg School of Medicine and stayed there for his internship and residency training in Internal Medicine. From there he moved on to Johns Hopkins University’s Oncology Center where he completed a fellowship in Hematology and Medical Oncology.[1]
After completing his education he took on the role of physician-scientist at Wayne State University/Karmanos Cancer Institute in Detroit, after which he joined the faculty of the Division of Hematology/Oncology at the University of Michigan. In addition to caring for patients with thoracic malignancies, he serves as the Associate Division Chief for Faculty Development and Education and the Associate Director of the Hematology/Oncology Fellowship Program.
Dr. Kalemkerian has served on and led numerous grant review sections, editorial boards, and committees of national and international professional societies. He is a former chair of the NCCN Small Cell Lung Cancer Guideline Panel and the ASCO Scientific Program Committee’s Metastatic NSCLC and Professional Development and Education Tracks.
Research
Dr. Kalemkerian is actively involved in academic research at Rogel Cancer Center, with a particular interest in clinical and translational trials for thoracic cancers. Clinical trials he is currently participating in include:
- Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
- A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
He is also a prolific author and speaker. He has given over 230 invited lectures, authored more than 200 research articles, reviews, commentaries, and book chapters, and edited two books on lung cancer. Recent publications include:
Systemic Therapy for Small-Cell Lung Cancer: ASCO-Ontario Health (Cancer Care Ontario) Guideline.
Humera Khurshid, Nofisat Ismaila, Jessica Bian, Raetasha Dabney, Millie Das, Peter Ellis, Jill Feldman, Christine Hann, Swati Kulkarni, Janessa Laskin, Rami Manochakia…>; Journal of Clinical Oncology. 2023 Oct 11
Short Report of a Phase II Trial of Nintedanib in Recurrent Malignant Pleural Mesothelioma (MPM).
Antoinette J Wozniak, Bryan Schneider, Gregory P Kalemkerian, Bobby Daly, Wei Chen, Jaclyn Ventimiglia, Misako Nagasaka, Marjorie G Zauderer>; Clinical Lung Cancer. 2023 Sep 1
Davit Zohrabyan, Nune Karapetyan, Samvel Danielyan, Tatul Saghatelyan, Liana Safaryan, Samvel Bardakhchyan, Gevorg Tamamyan, Martin Harutyunyan, Marine Rushanyan, Goha…>; Journal of Thoracic Oncology. 2023 Apr 1
